-
Je něco špatně v tomto záznamu ?
Accelerated reactive dissolution model of drug release from long-acting injectable formulations
E. Sonntag, J. Kolář, S. Djukaj, R. Lehocký, F. Štěpánek
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- antipsychotika * MeSH
- injekce intramuskulární MeSH
- léky s prodlouženým účinkem MeSH
- lidé MeSH
- prekurzory léčiv * MeSH
- rozpustnost MeSH
- suspenze MeSH
- uvolňování léčiv MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Long-acting injectable formulations represent a rapidly emerging category of drug delivery systems that offer several advantages compared to orally administered medicines. Rather than having to frequently swallow tablets, the medication is administered to the patient by intramuscular or subcutaneous injection of a nanoparticle suspension that forms a local depot from which the drug is steadily released over a period of several weeks or months. The benefits of this approach include improved medication compliance, reduced fluctuations of drug plasma level, or the suppression of gastrointestinal tract irritation. The mechanism of drug release from injectable depot systems is complex, and there is a lack of models that would enable quantitative parametrisation of the process. In this work, an experimental and computational study of drug release from a long-acting injectable depot system is reported. A population balance model of prodrug dissolution from asuspension with specific particle size distribution has been coupled with the kinetics of prodrug hydrolysis to its parent drug and validated using in vitro experimental data obtained from an accelerated reactive dissolution test. Using the developed model, it is possible to predict the sensitivity of drug release profiles to the initial concentration and particle size distribution of the prodrug suspension, and subsequently simulate various drug dosing scenarios. Parametric analysis of the system has identified the boundaries of reaction- and dissolution-limited drug release regimes, and the conditions for the existence of a quasi-steady state. This knowledge is crucial for the rational design of drug formulations in terms of particle size distribution, concentration and intended duration of drug release.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016706
- 003
- CZ-PrNML
- 005
- 20231026105619.0
- 007
- ta
- 008
- 231013s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejpb.2023.06.003 $2 doi
- 035 __
- $a (PubMed)37321329
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Sonntag, Erik $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague 6, Czech Republic
- 245 10
- $a Accelerated reactive dissolution model of drug release from long-acting injectable formulations / $c E. Sonntag, J. Kolář, S. Djukaj, R. Lehocký, F. Štěpánek
- 520 9_
- $a Long-acting injectable formulations represent a rapidly emerging category of drug delivery systems that offer several advantages compared to orally administered medicines. Rather than having to frequently swallow tablets, the medication is administered to the patient by intramuscular or subcutaneous injection of a nanoparticle suspension that forms a local depot from which the drug is steadily released over a period of several weeks or months. The benefits of this approach include improved medication compliance, reduced fluctuations of drug plasma level, or the suppression of gastrointestinal tract irritation. The mechanism of drug release from injectable depot systems is complex, and there is a lack of models that would enable quantitative parametrisation of the process. In this work, an experimental and computational study of drug release from a long-acting injectable depot system is reported. A population balance model of prodrug dissolution from asuspension with specific particle size distribution has been coupled with the kinetics of prodrug hydrolysis to its parent drug and validated using in vitro experimental data obtained from an accelerated reactive dissolution test. Using the developed model, it is possible to predict the sensitivity of drug release profiles to the initial concentration and particle size distribution of the prodrug suspension, and subsequently simulate various drug dosing scenarios. Parametric analysis of the system has identified the boundaries of reaction- and dissolution-limited drug release regimes, and the conditions for the existence of a quasi-steady state. This knowledge is crucial for the rational design of drug formulations in terms of particle size distribution, concentration and intended duration of drug release.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a antipsychotika $7 D014150
- 650 12
- $a prekurzory léčiv $7 D011355
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a rozpustnost $7 D012995
- 650 _2
- $a injekce intramuskulární $7 D007273
- 650 _2
- $a suspenze $7 D013535
- 650 _2
- $a léky s prodlouženým účinkem $7 D003692
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kolář, Jiří $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Djukaj, Suada $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Lehocký, Róbert $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Štěpánek, František $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague 6, Czech Republic. Electronic address: Frantisek.Stepanek@vscht.cz
- 773 0_
- $w MED00001640 $t European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V $x 1873-3441 $g Roč. 189, č. - (2023), s. 122-132
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37321329 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105613 $b ABA008
- 999 __
- $a ok $b bmc $g 2000305 $s 1203068
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 189 $c - $d 122-132 $e 20230614 $i 1873-3441 $m European journal of pharmaceutics and biopharmaceutics $n Eur J Pharm Biopharm $x MED00001640
- LZP __
- $a Pubmed-20231013